TrialInvestigational new drugs2019

Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.

Clinton Yam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.